Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all cause mortality
Objective<br/> Experimental evidence has shown potential cardioprotective actions of phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether phosphodiesterase type-5 inhibitor (PDE5i) use in patients with type 2 diabetes, with high attendant cardiovascular risk, was associated wi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
BMJ Publishing Group
2016
|